Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 7:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 1,760 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #1 Clear all

Conditions: Fatigue
Interventions: Alpinia galanga formulation, Theacrine formulation, Caffeine formulation, Placebo; Dietary Supplement
Lead sponsor: Supplement Formulators, Inc.; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
Interventions: Bosentan, Gemcitabine, Nab-paclitaxel, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Healthy Participants
Interventions: LY4064809 Test Formulation, LY4064809 Reference Formulation; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Non-segmental Vitiligo
Interventions: VYN201 Gel, Vehicle Gel; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 39 more

Conditions: Healthy Volunteers
Interventions: Maribavir Commercial Tablet Formulation, Maribavir Pediatric Powder-for-oral Suspension Formulation, Rabeprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Non-small Cell Lung Cancer
Interventions: Pertuzumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 8
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 5 more

Conditions: Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions: GRT7014 - Abuse Deterrend Tablet, Norco 5Mg-325Mg Tablet; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Inflammatory Response
Interventions: Blueberry-protein gel, Blueberry gel, Placebo; Dietary Supplement
Lead sponsor: Appalachian State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Inactivated Influenza Vaccine
Interventions: 2005-2006 trivalent inactivated influenza vaccine; Biological
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 42 Days to 84 Days
Enrollment: 1,375 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Solid Tumors
Interventions: Idasanutlin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 9
States / cities: Aurora, Colorado • New Haven, Connecticut • St Louis, Missouri + 5 more

Conditions: Neoplasms
Interventions: BXQ-350; Drug
Lead sponsor: Bexion Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Lexington, Kentucky • Cincinnati, Ohio • Columbus, Ohio

Conditions: Healthy Volunteers, Vitamin A
Interventions: Unfortified bouillon plus vitamin A in oil, Bouillon fortified with vitamin A #1 plus unfortified oil, Bouillon fortified with vitamin A #2 plus unfortified oil; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: Seltorexant; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: Encorafenib capsule formulation (CAP), Encorafenib first formulation, Encorafenib second formulation, Rabeprazole tablet; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: ICU Acquired Weakness
Interventions: FDY-5301, Placebo; Drug · Other
Lead sponsor: Faraday Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Torrance, California • Gainesville, Florida • Boston, Massachusetts + 2 more

Conditions: Healthy Adult Subjects
Interventions: TTYP01, Radicava, Radicava ORS; Drug
Lead sponsor: Shanghai Auzone Biological Technology Co., Ltd.; Industry
Eligibility: 20 Years to 45 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions: Trabodenoson, Latanoprost, Timolol; Drug
Lead sponsor: Inotek Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Bristol, Tennessee

Conditions: Mycosis Fungoides
Interventions: 0.04% Mechlorethamine gel; Drug
Lead sponsor: Yaupon Therapeutics; Industry
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 11
States / cities: Stanford, California • Chicago, Illinois • New York, New York + 7 more

Conditions: Alzheimer Disease
Interventions: AC-OLE-01-VA; Drug
Lead sponsor: Cerecin; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Schizophrenia
Interventions: Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg, Placebo depot, Placebo tablets; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 937 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 39
States / cities: Cerritos, California • Escondido, California • Garden Grove, California + 31 more

Conditions: Coronavirus (SARS-CoV)
Interventions: Aluminum hydroxide, Placebo, SARS-CoV; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer, Pharmacokinetics of Enzalutamide
Interventions: Enzalutamide tablet, Enzalutamide capsule; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Denver, Colorado • Chicago, Illinois • Pittsburgh, Pennsylvania + 1 more

Conditions: Healthy Volunteers
Interventions: AGN-223575 Formulation A, AGN-223575 Formulation B, AGN-223575 Formulation C, AGN-223575 Vehicle; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Myelofibroses
Interventions: TP-3654; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Secaucus, New Jersey

Search by objective public record fields.

Evaluate the Effectiveness and Safety of the Alpinia Galanga Formulation, Theacrine Formulation, and Caffeine Formulation on Fatigue, Mental Acuity, and Cognitive Health

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

A Study of LY4064809 in Healthy Adult Participants

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

A Study of Maribavir Pediatric Formulation in Healthy Adult Participants

Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults

Blueberry-protein Supplementation and Exercise

Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age

A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors

Continued Treatment for Participants Enrolled in Studies of BXQ-350

Evaluation of Vitamin A Absorption From Fortified Bouillon

A Study of Seltorexant in Healthy Participants

A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations

Evaluation of FDY-5301 in Major Trauma Patients in ICU

Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides

A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

SARS Coronavirus Vaccine (SARS-CoV)

Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients

A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects

TP-3654 Food Effect Study